Loading
Latest filing published 01 Apr 2025 for Perspective Therapeutics, Inc., €46k.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Lori A. Woods (chief executive) discloses dealings in Perspective Therapeutics, Inc. to SEC (Form 4). The record holds 27 filings, for trades running from 14 November 2018 to 31 March 2025.
Every open-market trade on record is a purchase: 15 purchases worth €379k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant and 11 option exercises. Since January 2025: 1 purchase and no sales on the market.
In size, the median ticket on the buying side is €21k. 11 out of 15 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The latest filing, published on 1 April 2025, reports an open-market purchase of €46k in Perspective Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations